- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Phentermine-topiramate and GLP-1 agonists best drugs for weight loss in obese: Lancet study
China: Phentermine-topiramate and GLP-1 receptor agonists seemed to be the best drugs for reducing weight in adults with overweight and obesity, suggests a recent study. Further, semaglutide was found to be most effective amongst the GLP-1 agonists.
When lifestyle modifications fail in adults with overweight and obesity, pharmacotherapy provides an option. Qingyang Shi, Sichuan University, Chengdu, China, and colleagues summarised the latest evidence for the benefits and harms of weight-lowering drugs in a systematic review and network meta-analysis.
The researchers searched the online databases from inception to March 23, 2021, for randomized controlled trials of weight-lowering drugs in adults with overweight and obesity. The evidence was summarized and Grading of Recommendations Assessment, Development, and Evaluation frameworks were applied to rate the certainty of the evidence, calculate the absolute effects, categorize interventions, and present the findings.
The search identified 14 605 citations, of which 143 eligible trials enrolled 49 810 participants.
Key findings include:
- Except for levocarnitine, all drugs lowered bodyweight compared with lifestyle modification alone; all subsequent numbers refer to comparisons with lifestyle modification.
- High to moderate certainty evidence established phentermine–topiramate as the most effective in lowering weight (odds ratio [OR] of ≥5% weight reduction 8·02; mean difference [MD] of percentage bodyweight change −7·97) followed by GLP-1 receptor agonists (OR 6·33; MD −5·76).
- Naltrexone–bupropion (OR 2·69), phentermine–topiramate (2·40) GLP-1 receptor agonists (2·17), and orlistat (1·72) were associated with increased adverse events leading to drug discontinuation.
- In a post-hoc analysis, semaglutide, a GLP-1 receptor agonist, showed substantially larger benefits than other drugs with a similar risk of adverse events as other drugs for both likelihoods of weight loss of 5% or more (OR 9·82) and percentage body weight change (MD −11·41).
The authors concluded, "phentermine–topiramate and GLP-1 receptor agonists n adults with overweight and obesity, proved the best drugs in reducing weight; of the GLP-1 agonists, semaglutide might be the most effective."
Reference:
The study titled, "Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials," was published in The Lancet.
DOI: https://doi.org/10.1016/S0140-6736(21)01640-8
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751